Add office photos
Employer?
Claim Account for FREE
Biocon Limited
3.9
based on 1.8k Reviews
Company Overview
Associated Companies
Company Locations
About Biocon Limited
Founded in1978 (46 yrs old)
India Employee Count1k-5k
Global Employee Count5k-10k
India HeadquartersBangalore Rural, Karnataka, India
Office Locations
--
Websitebiocon.com
Primary Industry
Other Industries
Are you managing Biocon Limited's employer brand? To edit company information,
claim this page for free
We are a global biopharmaceutical company which believes that everyone has a right to affordable quality medicines.
Powered by advanced therapy platforms, our 13,500+ employees blend heart, science and creativity to make better healthcare solutions.
Our 4 global businesses include generics, biosimilars, research services and novel biologics. They represent Biocon’s risk-balanced strategy, underpinned by agile network connections, a robust pipeline and a timely ‘emerging markets’ orientation.
We have leveraged India’s value advantage of unmatched scientific talent and cost-competitive manufacturing to deliver scale, speed and quality. By making medicines more easily accessible for patients across the globe, we’re working towards achieving health equity.
We are committed to providing everyone, everywhere, affordable access to a speciality portfolio of medicines.
We are steadfastly investing in developing novel therapies for diabetes, oncology and immunology. We are strengthening our global reach and economies of scale.
Mission: To be an integrated biotechnology enterprise of global distinction. Essential to this mission is excellence in:
Intellectual asset creation through discovery, research and development
State-of-the-art manufacturing capabilities
Internationally benchmarked quality and regulatory systems
New medical insight through disease-specific clinical research
Customer relationship through outstanding products and services
Human resource development through training, mentoring and empowering
Management of research and business partnerships
Vision: To enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners and healthcare systems across the globe.
Managing your company's employer brand?
Claim this Company Page for FREE
Brands of Biocon
Biocon Research
4.1
• 60 reviews
Biocon Foundation
2.0
• 11 reviews
Report error
Biocon Limited Ratings
based on 1.8k reviews
Overall Rating
3.9/5
How AmbitionBox ratings work?
5
744
4
578
3
251
2
96
1
121
Category Ratings
3.8
Job Security
3.8
Work-Life Balance
3.7
Company Culture
3.7
Skill Development
3.6
Salary & Benefits
3.5
Work Satisfaction
3.2
Promotions/Appraisal
Biocon Limited is rated 3.9 out of 5 stars on AmbitionBox, based on 1.8k company reviews.This rating reflects an average employee experience, indicating moderate satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Biocon Limited
based on 1.7k reviews
3.9
Rated by 258 Women
Rated 3.8 for Job Security and 3.7 for Work-Life Balance
3.9
Rated by 1.4k Men
Rated 3.8 for Job Security and 3.8 for Work-Life Balance
Work Policy at Biocon Limited
based on 186 reviews in last 6 months
Work from office
84%
Hybrid
12%
Permanent work from home
4%
Biocon Limited Reviews
Top mentions in Biocon Limited Reviews
+ 5 more
Compare Biocon Limited with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 3.9/5 based on 1.8k reviews | 4.1/5 based on 5.5k reviews | 4.1/5 based on 6.5k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | Job Security Work-Life balance | Salary & Benefits Job Security Skill development | Skill development Salary & Benefits Work-Life balance | Skill development Work-Life balance Salary & Benefits |
Critically Rated for | Promotion/Appraisals | No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 84% employees reported | Work from office 87% employees reported | Work from office 72% employees reported | - |
Rating by Women Employees | 3.9 Good rated by 258 women | 4.1 Good rated by 404 women | 4.1 Good rated by 626 women | - no rating available |
Rating by Men Employees | 3.9 Good rated by 1.4k men | 4.1 Good rated by 4.8k men | 4.1 Good rated by 5.5k men | - no rating available |
Job Security | 3.8 Good | 3.9 Good | 3.7 Good | 4.0 Good |
View more
Biocon Limited Salaries
3.6
rated by 1.8k employees for salariesJunior Executive
(546 salaries)
Unlock
₹2 L/yr - ₹5.1 L/yr
Deputy Manager
(450 salaries)
Unlock
₹7 L/yr - ₹18 L/yr
Executive Production
(265 salaries)
Unlock
₹3 L/yr - ₹6.2 L/yr
Senior Scientist
(216 salaries)
Unlock
₹4.7 L/yr - ₹11.5 L/yr
Principal Scientist
(158 salaries)
Unlock
₹6 L/yr - ₹15.1 L/yr
Scientist
(113 salaries)
Unlock
₹2.8 L/yr - ₹7.1 L/yr
Executive Engineer
(107 salaries)
Unlock
₹3.2 L/yr - ₹6.3 L/yr
Territory Business Manager
(95 salaries)
Unlock
₹3.4 L/yr - ₹7.9 L/yr
QC Executive
(82 salaries)
Unlock
₹2.7 L/yr - ₹5.3 L/yr
Associate Director
(62 salaries)
Unlock
₹25 L/yr - ₹47 L/yr
Biocon Limited Interview Questions
Interview questions by designation
Top interview questions and answers
Get interview-ready with top interview questions
Interview Process at Biocon Limited
based on 32 interviews in last 1 year
Interview Experience
4.2
Good
Difficulty level
Easy
22%
Moderate
67%
Hard
11%
People are getting interviews through
based on 90 Biocon Limited interviews
Job Portal
27%
Referral
19%
Walkin
16%
Company Website
13%
*25% candidates got the interview through other sources
High confidence
Biocon Limited Jobs
Biocon Limited News
View all
Biocon Sells Syngene’s Shares Worth Rs 686 Crore
- Biocon Ltd. sold Syngene shares worth Rs 686 crore via block deals on the BSE, reducing its stake while maintaining majority ownership at 52.46%.
- The transaction took place in the open market and none of the buyers belong to the promoter, promoter group, or group companies.
- Biocon's subsidiary Biocon Biologics Ltd. received US FDA approval for Yesintek, a biosimilar for Johnson & Johnson's reference product, Stelara.
- For the second quarter of fiscal 2025, Biocon's consolidated net profit fell 84.3% to Rs 27.1 crore compared to the year-ago period.
Bloomberg Quint | 10 Dec, 2024
AdvantageClub.ai bags $4M in funding led by Axilor Ventures
- AdvantageClub.ai, a company specializing in employee engagement solutions, has raised $4 million in a funding round led by Axilor Ventures.
- The funding round also saw participation from AFG Ventures, Prasanna Sarkar, Bytez Ventures, and existing ventures, bringing the total funding raised by AdvantageClub.ai to $11 million.
- The company plans to utilize the funding to expand into the US and Asia, strengthen its position in rewards and recognition, and develop wellness programs.
- AdvantageClub.ai, founded in 2016, provides its services to clients such as Tech Mahindra, HCL, Concentrix, Hexaware, Biocon, Tata Steel, and Air India.
Yourstory | 2 Dec, 2024
Biocon Biologics Receives US FDA Nod For Yesintek, A Biosimilar to J&J's Stelara
- Biocon Biologics has received FDA approval for Yesintek, a biosimilar for Johnson & Johnson's Stelara.
- Yesintek, a monoclonal antibody, will treat Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
- This approval will provide affordable access to high-quality biosimilars for millions of patients worldwide.
- Biocon Biologics is set to commercialize Yesintek in the United States by February 22, 2025.
Bloomberg Quint | 1 Dec, 2024
Five Stocks To Buy: IREDA, Mazagon Dock, Ircon, Ashok Leyland And Biocon
- Analysts have buy calls on IREDA, Mazagon Dock, Ircon, Ashok Leyland And Biocon today.
- IREDA received a 'buy' call with a target price of Rs 220 per share.
- Mazagon Dock Shipbuilders has a 'buy' recommendation with a target price of Rs 4,900 per share.
- Ircon International has a 'buy' recommendation with a target price of Rs 225 per share.
- Ashok Leyland has a 'buy' call with a target price of Rs 250 per share.
- Biocon Ltd. has a 'buy' call with a target price of Rs 380 per share.
Bloomberg Quint | 28 Nov, 2024
Biocon - 'VAI’ Brings Much-Needed Regulatory Respite, Says Motilal Oswal
- Biocon has received a Voluntary Action Indicated (VAI) status from the US Food and Drug Administration (FDA).
- Motilal Oswal Financial Services believes that this brings much-needed regulatory respite for Biocon.
- The brokerage maintains a Neutral stance on the stock, as the current valuation already captures the earnings upside.
- The VAI status is a positive development for Biocon in terms of US FDA compliance.
Bloomberg Quint | 11 Nov, 2024
Biocon Biologics Confident Of Tackling Pricing Pressures, Ready To Compete
- Biocon Biologics' Chief Executive Officer and Managing Director Shreehas Tambe is confident of tackling pricing pressures in the biosimilar market.
- Tambe emphasized that pricing is not a challenge for them, but rather a differentiator due to their competitive setup and cost structure.
- Biocon Biologics, as an emerging markets' player, focuses on a frugal cost structure and affordability index, driving the company's growth.
- Biocon Ltd., the parent company of Biocon Biologics, reported an over 84% decline in profit for the September quarter, while biosimilar sales were up 4%.
Bloomberg Quint | 5 Nov, 2024
Biocon Share Price Recovers From Four-Month Low After Q2 Profit Beats Estimates
- Biocon's net profit declined 84.3% on year to Rs 27.1 crore, against Bloomberg's consensus estimate of Rs 24 crore.
- Biocon share price recovered from its four-month low after the company reported its Q2 results.
- Revenue was up 3.7% to Rs 3,590 crore compared to Rs 3,623 crore estimated.
- Motilal Oswal stated that despite challenges, Biocon delivered improved profitability sequentially thanks to a strong revival in its Syngene business.
Bloomberg Quint | 31 Oct, 2024
%20Syngene%20is%20a%20subsidiary%20of%20Biocon%20Ltd..jpg?rect=0%2C1155%2C8153%2C4280&w=1200&auto=format%2Ccompress&ogImage=true)
Biocon reports net loss of ₹16 crore for Q2FY25
- Biocon reports net loss of ₹16 crore for Q2FY25
- Revenue increases by 4% to reach ₹3,590 crore in Q2FY25
- EBITDA decreases to ₹718 crore with a margin of 20%
- Biosimilars business shows strong growth, while Generics segment faces pressure
HinduBusinessLine | 30 Oct, 2024
Biocon Biologics' Bengaluru Facility Receives Voluntary Action Classification From FDA
- Biocon Biologics' drug substance facility in Bengaluru has received a voluntary action classification from the US FDA.
- The classification relates to the cGMP inspection conducted between Feb. 20-28, 2024, and pertains to the supply of rh-Insulin drug substance to the United States.
- While objectionable conditions were found and documented during the inspection, the FDA is not prepared to take regulatory action.
- Biocon Biologics remains committed to global standards of quality and compliance.
Bloomberg Quint | 30 Oct, 2024
Q2 Results Live Updates: Paisalo Digital Profit Rises; L&T Projected To Report Muted Earnings
- L&T projected to report muted Q2 earnings.
- Paisalo Digital records 4.9% rise in net profit for Q2.
- 77 companies set to declare Q2 earnings today.
- Tata Power, Dabur India, Biocon among the companies announcing Q2 results.
Bloomberg Quint | 30 Oct, 2024
Powered by
Biocon Limited Offices
Compare Biocon Limited with
Torrent Pharmaceuticals
3.9
Lupin
4.2
Zydus Lifesciences
4.2
Glenmark Pharmaceuticals
4.0
Aurobindo Pharma
4.0
DIVI'S Laboratories
3.8
Piramal Group
3.9
Biocon Biologics
3.6
Panacea Biotec
3.8
LifeCell International
3.4
Praj Industries
4.1
Bharat Biotech International
3.1
Serum Institute of India
4.2
Transasia Bio-Medicals
3.2
Indian Immunologicals
4.1
Jubilant Biosys
3.8
Avantor
3.7
Novozymes South Asia
4.1
JK Agri Genetics
3.9
Kemwell Biopharma
3.7
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Companies Similar to Biocon Limited
DRJ & CO
Architecture & Interior Design
5.0
• 1 reviews
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.1
• 5.5k reviews
Cipla
Manufacturing, Pharma
4.1
• 6.5k reviews
Torrent Pharmaceuticals
Pharma
3.9
• 2.4k reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.2
• 5.8k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.2
• 5.8k reviews
Glenmark Pharmaceuticals
Pharma
4.0
• 2.7k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 4.6k reviews
DIVI'S Laboratories
Pharma
3.8
• 1.3k reviews
Piramal Group
Pharma
3.9
• 1.1k reviews
Biocon Biologics
Biotechnology
3.6
• 744 reviews
Panacea Biotec
Biotech & Life sciences, Biotechnology
3.8
• 672 reviews
Biocon Limited FAQs
When was Biocon Limited founded?
Where is the Biocon Limited headquarters located?
How many employees does Biocon Limited have in India?
Does Biocon Limited have good work-life balance?
Is Biocon Limited good for career growth?
What are the pros and cons of working in Biocon Limited?
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
70 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
